Innate Pharma (IPH)

Paris


	Symbol		Exchange		Currency
	IPH		Paris		EUR	Real-time
	IPHA		NASDAQ		USD	Real-time
	IPHYF		OTC Markets		USD	Delayed
	IPH		TradeGate		EUR	Delayed

Currency in EUR

1.6940

+0.0320(+1.81%)

Closed10/12

Fair Value

Day's Range

1.6240

1.8260

52 wk Range

1.3320

2.8000

IPH Income Statement

Explore the detailed Innate Pharma income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Innate Pharma's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

85.45

69.77

24.7

57.67

61.64

Total Revenues Growth

-9.05%

-18.35%

-64.6%

+133.47%

+6.88%

Cost Of Revenues

62.9

49.71

47

51.66

56.02

Gross Profit

22.55

20.07

-22.3

6.01

5.62

Gross Profit Growth

-7.56%

-11.03%

-211.14%

+126.95%

-6.52%

Gross Profit Margin %

26.39%

28.76%

-90.28%

10.42%

9.12%

Other Operating Expenses, Total

20.98

18.99

25.52

22.44

18.29

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+8.97%	-9.49%	+34.44%	-12.1%	-18.49%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	20.98	18.99	25.52	22.44	18.29
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

1.58

1.08

-47.83

-16.43

-12.67

Operating Income Growth

-69.39%

-31.49%

-4,532.34%

+65.66%

+22.87%

EBIT Margin %

1.84%

1.55%

-193.6%

-28.48%

-20.55%

Net Interest Expenses

1.42

0.22

0.02

0.26

2.54

Net Interest Expenses Growth

-4.32%

-84.25%

-93.27%

+1,620%

+883.33%

Interest Expense, Total

-0.2

-0.34

-0.31

-0.29

-0.64

Interest And Investment Income

1.62

0.56

0.33

0.55

3.18

Other Non Operating Expenses, Total

4.88

-2.13

2.33

-0.81

2.56

EBT, Excl. Unusual Items

7.87

-0.83

-45.48

-16.97

-7.57

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-

-41

-

EBT, Incl. Unusual Items

7.87

-0.83

-45.48

-57.97

-7.57

EBT, Incl. Unusual Items Growth

+189.69%

-110.54%

-5,385.89%

-27.47%

+86.94%

EBT, Incl. Unusual Items Margin

9.21%

-1.19%

-184.1%

-100.52%

-12.28%

Income Tax Expense

-

-

-

-

-

Net Income to Company

-20.76

-63.98

-52.81

-58.1

-7.57

Minority Interest

-

-

-

-

-

Net Income

-20.76

-63.98

-52.81

-58.1

-7.57

Net Income Growth

-780.85%

-208.22%

+17.47%

-10.02%

+86.97%

Net Income Margin %

-24.29%

-91.7%

-213.78%

-100.74%

-12.28%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

7.87

-0.83

-45.48

-57.97

-7.57

Basic EPS - Continuing Operations

0.12

-0.01

-0.57

-0.73

-0.09

Basic EPS - Continuing Operations Growth

+126.69%

-108.93%

-5,344.13%

-27.32%

+87.07%

Diluted EPS - Continuing Operations

0.12

-0.01

-0.57

-0.73

-0.09

Diluted EPS - Continuing Operations Growth

+135.19%

-108.93%

-5,344.13%

-27.68%

+87.11%

Basic Weighted Average Shares Outstanding

66.91

78.93

79.54

79.64

80.45

Diluted Weighted Average Shares Outstanding

66.91

78.93

79.54

79.64

80.45

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

17.25

13.31

-43.23

-12.02

-7.58

EBITDA Growth

+38.2%

-22.88%

-424.91%

+72.19%

+36.96%

EBITDA Margin %